MCF2L and leiomyosarcoma: Methylation modifications in other of the identified genes (PCDH20, CDEB, KCNQ1, MCF2L, LTB4R and PRODH)41–44 have been described in carcinomas but their role in the pathogenesis of leiomyosarcoma progression has not been reported (apart from PCDH2 and PRODH45), and should be further explored.